文献速递胸部MR

扩散加权MRI及表观扩散系数作为预后生物标志物评估化疗-抗血管生成治疗的IV期非小细胞肺癌:一项前瞻性、单臂、开放标签临床试验(BevMar)

Diffusion weighted MRI and apparent diffusion coefficient as a prognostic biomarker in evaluating chemotherapy-antiangiogenic treated stage IV non-small cell lung cancer: A prospective, single-arm, open-label, clinical trial (BevMar).
PubMed 文献 · Eur J Radiol · 2024-06-09

前瞻性单臂开放标签临床试验于2014年9月至2020年12月纳入18例IV期非小细胞肺癌患者,接受化疗-抗血管生成联合治疗,基线与治疗后2、4、16周行DW-MRI并计算ΔADC。ΔADC≥-3组中位OS为18个月(95%CI 7-46),ΔADC<-3组为7个月(95%CI 5-9),HR 0.12(95%CI 0.03-0.61,p=0.003)。作者认为肿瘤ADC早期变化可能提示更长OS,DW-MRI可作为评估治疗反应的早期生物标志物。

要点

  • ΔADC≥-3(即ADC下降不超过3个单位)组中位OS 18个月,ΔADC<-3组7个月。
  • ΔADC≥-3组死亡风险显著低于ΔADC<-3组,HR 0.12(95%CI 0.03-0.61,p=0.003)。
  • DW-MRI于基线及治疗后2、4、16周采集,ΔADC为治疗前后ADC差值。

核心结论

  • 肿瘤ADC值的早期变化可能提示更长的总生存期,DW-MRI可能作为接受化疗联合抗血管生成治疗患者评估治疗反应的早期生物标志物。

研究设计与样本

  • 前瞻性、单臂、开放标签临床试验,2014年9月至2020年12月开展,最终分析纳入18例IV期非小细胞肺癌患者,接受化疗-抗血管生成联合治疗,于基线及治疗开始后2、4、16周行DW-MRI,计算治疗前后ADC差值(ΔADC),随访5年评估总生存期。

诊断标准与关键数值

  • 以ΔADC≥-3为阈值:该组中位OS 18个月(95%CI 7-46),ΔADC<-3组中位OS 7个月(95%CI 5-9),HR 0.12(95%CI 0.03-0.61,p=0.003)。

临床应用与阅片要点

  • 作者认为肿瘤ADC早期变化可能提示更长OS,DW-MRI可作为评估化疗联合抗血管生成治疗反应的早期生物标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: When treating Lung Cancer, it is necessary to identify early treatment failure to enable timely therapeutic adjustments. The Aim of this study was to investigate whether changes in tumor diffusion during treatment with chemotherapy and bevacizumab could serve as a predictor of treatment failure.

MATERIAL AND METHODS: A prospective single-arm, open-label, clinical trial was conducted between September 2014 and December 2020, enrolling patients with stage IV non-small cell lung cancer (NSCLC). The patients were treated with chemotherapy-antiangiogenic combination. Diffusion weighted magnetic resonance imaging (DW-MRI) was performed at baseline, two, four, and sixteen weeks after initiating treatment. The differences in apparent diffusion coefficient (ADC) values between pre- and post-treatment MRIs were recorded as Delta values (ΔADC). We assessed whether ΔADC could serve as a prognostic biomarker for overall survival (OS), with a five year follow up.

RESULTS: 18 patients were included in the final analysis. Patients with a ΔADC value ≥ -3 demonstrated a significantly longer OS with an HR of 0.12 (95 % CI; 0.03- 0.61; p = 0.003) The median OS in patients with a ΔADC value ≥ -3 was 18 months, (95 % C.I; 7-46) compared to 7 months (95 % C.I; 5-9) in those with a ΔADC value < -3.

CONCLUSION: Our findings suggest that early changes in tumor ADC values, may be indicative of a longer OS. Therefore, DW-MRI could serve as an early biomarker for assessing treatment response in patients receiving chemotherapy combined with antiangiogenic therapy.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Grundberg O, Skribek M, Swerkersson S, et al. Diffusion weighted MRI and apparent diffusion coefficient as a prognostic biomarker in evaluating chemotherapy-antiangiogenic treated stage IV non-small cell lung cancer: A prospective, single-arm, open-label, clinical trial (BevMar). Eur J Radiol. 2024. PMID: 38954912. doi:10.1016/j.ejrad.2024.111557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。